TRXB

10.3156.12%
AZ

Ali Zarrin

Chief Scientific Officer & Executive Director of Drug Discovery

Dr. Ali Zarrin, PhD, serves as Executive Director of Drug Discovery at TRex Bio and serves as Chief Scientific Officer since August 2025. He served as Head of Discovery at TRex Bio until September 2025. Dr. Zarrin joined Genentech Early Research and Development where he was instrumental in leading several transformational initiatives to advance multiple therapeutic programs from early discovery research covering diverse mechanistic pathways for cancer, inflammatory and autoimmune indications. He also led various disease area research strategies with the focus in autoimmune and inflammatory diseases. Dr. Zarrin has over 41 scientific publications (and 5 patents) on diverse topics in journals including Nature, Nature Immunology, Nature reviews Drug Discovery, Nature Reviews Immunology, Science, Science Signaling and PNAS. Dr. Zarrin obtained his BS in University of Minnesota and his PhD in Immunology from University of Toronto. He then carried out postdoctoral study in the lab of pioneering geneticist and molecular immunologist, Fred Alt, at HHMI/Harvard.

Positions